Business
Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor Summit
Ryan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Sat...
About this update from Satellos Bioscience Inc
[{"type":"text","content":"Satellos Bioscience to Present at Annual MDA Clinical and Scientific Conference and Insights in Research Investor SummitRyan Mitchell, PhD and Director of Business Development at Satellos to highlight SAT-3153 and Satellos' novel muscle regeneration technology in two forums at this year's MDA Conference and SummitToronto, Ontario--(Newsfile Corp. - March 17, 2023) - Satellos Bioscience Inc. (TSXV: MSCL) (OTCQB: MSCLF) (\"Satellos\" or the \"Company\"), a drug discovery company developing small molecule therapeutics to regenerate muscle as a new approach to treating disease conditions from muscular dystrophy to aging, today announced that Ryan Mitchell, PhD and Director of Business Development will present preclinical proof of concept data the Company has generated with its lead drug candidate SAT-3153. These data will be featured in a poster presentation at this year's Muscular Dystrophy Association (MDA) Clinical and Scientific Conference being held in Dallas, TX from March 19-23, 2023.In addition, Satellos has been invited to present its technological approach to correct muscle stem cell polarity and restore muscle regeneration as a novel therapeutic treatment for Duchenne muscular dystrophy (\"Duchenne\") and other life-altering muscular disorders in front of biopharmaceutical business development and venture capital investment professionals at the MDA's third annual Insights in Research Investor Summit. Dr. Mitchell will deliver the Company's presentation, titled \"Therapeutic Restoration of Muscle Regeneration in Duchenne,\" on Tuesday, March 21 at 11.40 am CDT. Outside of the presentation, Dr. Mitchell will be joined by Dr. Phil Lambert, Chief Technology Officer at Satellos, for meetings to discuss opportunities with biopharmaceutical, academic, clinical, philanthropic, investment and other stakeholders attending this year's conference. \"We view this opportunity to present in two different forums at the MDA's flagship annual event as a tangible sign of the progression of our science and the growing acceptance of our unique insights into the modulation of muscle stem cell polarity to induce muscle regeneration, in the absence of the dystrophin protein, as a potentially novel treatment for Duchenne patients regardless of their exon mutation status, level of background AAV antibodies or ambulatory status,\" said Frank Gleeso...